Cancer drugmaker Genmab's H1 revenue rises, lifts FY outlook

Genmab A/S

06/08/2026 16:12

Overview
Denmark biotech firm's H1 2026 revenue rose 25% yr/yr, driven by higher royalties and sales
Operating profit for H1 2026 increased slightly from a year earlier
Company raised full-year 2026 guidance on higher royalty revenues and product sales

Outlook
Genmab raises 2026 revenue guidance to $4.33 bln-$4.53 bln from $4.07 bln-$4.40 bln
Company now sees 2026 royalties at $3.63 bln-$3.75 bln, up from $3.44 bln-$3.69 bln
Genmab lifts 2026 net product sales/collaboration revenue forecast to $595 mln-$640 mln

Result Drivers
ROYALTY REVENUE - Co said higher net sales of DARZALEX and Kesimpta drove increased royalty revenue
EPKINLY SALES - Co said higher global net sales of EPKINLY contributed to revenue growth
PIPELINE INVESTMENT - Co said increased operating expenses were driven by investment in product pipeline and commercialization capabilities

Company press release: ID:nGNE3knt6N

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Operating Profit
 
$555 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 2 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Genmab A/S is DKK2,300.00, about 21.6% above its August 5 closing price of DKK1,892.00
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 20 three months ago

Reuters Recommended Reads
Aug 5 - BioCryst Pharmaceuticals Q2 revenue rises, lifts 2026 revenue guidance
Aug 6 - Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Aug 5 - Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)